Menu
HRSA released its latest drugmaker audit findings, which resulted in sanctions against India-based Aurobindo Pharma.

Third Straight HRSA Audit Finds Drugmaker 340B Overcharges in 2025

Bella Czajkowski, National Correspondent Views
For the third straight time in 2025, a federal audit has found a drug manufacturer overcharged covered entities for 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live